WHO in emergencies
14 February 2017 – The Democratic Republic of Congo declared the end of the yellow fever outbreak following a similar announcement in Angola on 23 December 2016, bringing an end to the outbreak in both countries after no new confirmed cases were reported from both countries for the past 6 months.
7 February 2017 - In emergencies, people are at higher risk of undernutrition and micronutrient deficiencies. Young children and women who are pregnant or breastfeeding are most vulnerable to undernutrition. Their bodies have a greater need for nutrients, such as vitamins and minerals, and are more susceptible to the harmful consequences of deficiencies. Acute malnutrition weakens the immune system, which then becomes more susceptible to developing diseases that can be fatal.
19 January 2017 – WHO has made important strides in its work during the Syrian crisis. A successful negotiation led to the evacuation of patients in critical condition from east Aleppo. Thousands more, fleeing besieged areas, received health care from mobile clinics. As the crisis continues, WHO's work in Syria remains crucial.
12 January 2017 – A mass vaccination campaign to protect more than 4 million children against a measles outbreak in conflict-affected states in north-eastern Nigeria is planned to start this week. The two-week campaign, which starts on 13 January, will target all children aged from 6 months to 10 years in accessible areas in Borno, Yobe and Adamawa States.
3 January 2017 – Intensified fighting in eastern Aleppo starting in July 2016 resulted in thousands of people injured and killed, and has deprived the civilian population of essential services, including health care. On 13 December, a plan to evacuate civilians was announced by WHO and partners. The first evacuations from besieged neighbourhoods in eastern Aleppo took place 15 December 2016.
23 December 2016 – An experimental Ebola vaccine was highly protective against the deadly virus in a major trial, according to results published today in The Lancet. The vaccine is the first to prevent infection from one of the most lethal known pathogens, and the findings add weight to early trial results published last year. The vaccine, called rVSV-ZEBOV, was studied in a trial involving 11 841 people in Guinea during 2015.